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Abstract 
Review on the t(6;11)(q27;q23) involving KMT2A 
(better known as MLL), and AFDN (Afadin), also 
known as AF6 or MLLT4. It occurs in acute myeloid 
leukemia, at times treatment-related leukemia, B 
lymphoblastic leukemia, and T-cell lymphoblastic 
leukemia. It carries a poor prognosis. 
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Identity 
Other names 
t(6;11)(q27;q23) MLL/MLLT4 
t(6;11)(q27;q23) MLL/AF6 
Note 
Herein below, the well-known term "MLL" will be 
used, instead of the poorly known term "KMT2A" 
A total of 135 different MLL rearrangements have 
been identified so far (Meyer et al., 2017). 
t(6;11)(q27;q23) G- banding - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics 
at theWaisman Center (left and middle), and Jean-Luc Lai (right). 
Clinics and pathology 
Note 
The incidence of 11q23 abnormalities in infants with 
acute lymphoblastic leukemia (ALL) ranges from 
60% to 80%., and from 4.5% to 5.7% among 
children who are older than 1 year and have ALL. 
The t(4;11)(q21;q23) MLL / AFF1, one of the most 
common 11q23 abnormalities, occurs in 2% of 
children and adults with ALL (Raimondi 2004). 
The incidence of 11q23 abnormalities in children 
with acute myeloid leukemia (AML) ranges from 
15% to 25%. In children younger than 2 years, the 
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peak incidence of 11q23/MLL gene rearrangements 
is 50%-60%. 
 
The incidence of 11q23 abnormalities in adults with 
AML is approximately 5% (Coenen et al., 2012).  
 
The incidence of 11q23 abnormalities among adult 
ALL cases is about 10% (Pui et al., 2004). 
Disease 
Translocation t(6;11) represent about 5% of acute 
leukemia with 11q23/MLL rearrangement and is 
more frequent in AML than in ALL. Different 
studies are available, each involving specific groups 
of patients, and they cannot be pooled in one meta-
analysis:  
 
In a large study on 2,345 acute leukemia patients 
with 11q23/MLL rearrangement, there were 1,420 
patients diagnosed with ALL (61%), 872 diagnosed 
with AML (37%) and 7 with MDS; 38 were mixed 
lineage leukemia (1.6%), 4 lymphomas, and 4 other. 
Of these 2,345 patients with MLL rearrangements, 
there was 95 cases of t(6;11). They represented 4% 
of the cases. Of these 95 cases, there were 26 ALL, 
68 AML, and 1 "other"; two of them were 2 
treatment related leukemia. Translocation t(6;11) 
was found in 7.8% of AML with MLL 
rearrangements and 1.8% of ALL with MLL 
rearrangements. There were 59 cases of T-cell ALL 
in this series of 2,345 acute leukemia patients. T-
ALL was mainly composed of AFDN (AF6, 
MLLT4) and MLLT1 (ENL) gene fusions: there 
were 23 AFDN (AF6, MLLT4) cases and 22 MLLT1 
(ENL) cases (Meyer et al., 2017).  
 
In a series of 550 cases with an 11q23 
rearrangement, 30 cases (5.5%) were shown to have 
a t(6;11)(q27;q23) There were 27 AMLs (26 de novo 
and 1 secondary, 3 M1, 2 M2, 8 M4, 1 M4/5, 13 M5) 
and 3 infant/childhood ALL, 1 being a T-ALL 
(Martineau et al., 1998).  
 
In a study of 756 childhood AML with 11q23 
rearrangement, 35 (5%) showed a t(6;11). The 
disease was an AML-M1 in 15%, AML-M2 in 6%, 
AML-M4 in 35%, AML-M5 in 41% (Balgobind et 
al., 2009).  
 
In a study of 415 adult AML cases (389 de novo and 
26 treatment-related AML), 54 were rearranged for 
MLL (31 MLL-fusions and 23 MLL partial tandem 
duplications (PTD)), 8 of which (26% of 11q23 
rearrangements, 1,9% of adult AML cases) were 
t(6;11) cases. There was 2 AML-M1, 1 AML-M2, 2 
AML-M4, 3 AML-M5 (Lavallee et al 2015). 11q23 
rearrangements were identified in 118 adult AML 
cases (85 de novo and 33 t-AML). A t(6;11) (n=17) 
was found in 14% of 11q23 rearrangements 
(Grossmann). Out of 2667 adults with de novo AML, 
16 patients (0.6%) were identified with t(6;11). there 
was 3 M1, 7 M4, 5 M5 (Blum et al., 2004). 
Clinics 
Central nervous system involvement was found in 
15% of 35 cases of childhood 11q23/MLL-
rearranged acute myeloid leukemia (Balgobind et al., 
2009) 
Epidemiology 
In the large study of 2,345 acute leukemia patients 
with 11q23-MLL-rearrangement, there was 876 
infants, 671 "pediatric" cases (infants excluded), and 
798 adults. Of the the 95 cases with t(6;11) in this 
study, median age was 19 years, with 3 infant, 44 
pediatric, and 48 adult cases; this abnormality is rare 
in infants (0,3%) and more frequent in children and 
adults: 6,6 and 6% respectively. Sex ratio was 
45M/50F. Mean age of T-cell ALL cases with 
t(6;11) was 17 years, with 14 pediatric and 9 adult 
cases. Sex ratio was 11M/12F (Meyer et al., 2017). 
In another study of t(6;11)(q27;q23) acute leukemia, 
median age was 30-35 years (range 0.5-72, with 2 
infant cases and 6 other children under 16). Sex ratio 
was 17M/13F (57%) (Martineau et al., 1998).  
 
In a study of 35 childhood AMLs, median age 12 
years (8% were infant cases, 34% were aged 2-9 yrs, 
and 57% were older children). M/F was 19/16 (54%) 
(Balgobind et al., 2009).  
 
On 8 adult AML cases : age were 22-58 years, and 
sex ratio was 3M/5F (Lavallee et al 2015). Median 
age of adults with de novo AML was 45 years (range 
22-65) in another study and sex ratio was 7M/8F 
(Blum et al., 2004). 
Prognosis 
Complete remission (CR) was obtained in 23 of 26 
AML cases, but median survival was only 12 months 
(Martineau et al., 1998). The 35 patients with a 
t(6;11)(q27;q23) had the worst outcome compared to 
other childhood 11q23/MLL-rearranged acute 
myeloid leukemia groups: 5-year event free survival 
(EFS) was 11% (± 5%) and 5-year overall survival 
(OS) was 22% (Balgobind et al., 2009). CR was 
achieved in 69% of adults with de novo AML (11 of 
16 patients), but CR duration was short (median 9 
months). The estimated probability of 2-year 
survival was 13%. Both long-term survivors 
received allogeneic stem cell transplantation. The 
estimated probability of 2-year survival of patients 
reported in the literature was 15% (Blum et al., 
2004). However, as there are many progresses in 
therapy, one cannot rely on survival studies made 10 
or 20 years ago. 
Cytogenetics 
t(6;11)(q27;q23) KMT2A/AFDN  
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Cytogenetics morphological 
In a series of 30 cases with t(6;11)(q27;q23), (27 
AMLs and 3 ALLs). The t(6;11) was the sole 
abnormality in 24 cases (at least in a subclone), 
+der(6)t(6;11), +8, +19 and +21 were found in 10% 
(3 times) each. All three patients with AML-M1 had 
additional abnormalities. (Martineau et al., 1998). In 
a series of adults with de novo AML, the t(6;11) was 
the sole abnormality in 12/15 cases; der(6)t(6;11) 
and +8 were found in one case each (Blum et al., 
2004) 
Cytogenetics molecular 
The t(6;11) translocation can escape recognition: 
chromosome 6 involvement may be overlooked and 
the abnormality may be missinterpreted as a 
del(11q), with conventional banding techniques; 
FISH techniques necessary. 
Genes involved and 
proteins 
Note 
Frequent KRAS and NRAS mutations were found 
(30% and 18% respectively) in AML adult cases and 
there was MECOM overexpression in 100% 
(Grossmann et al., 2013).There was high expression 
levels of NKX2-3 and MECOM in AML adult cases. 
(Lavallee et al 2015). Methylation of lysine79 of 
histone H3 (H3K79) is a prerequisite for 
maintenance of RNA transcription. MLL/AFF1 
(AF4), MLL/ MLLT3 (AF9), MLL/MLLT1 (ENL), 
MLL/MLLT10 (AF10) and MLL/AFDN (AF6, 
MLLT4), result in an increased and extended H3K79 
methylation (Meyer et al., 2017). 
KMT2A 
Location 
11q23.3 
Note 
Better known as MLL 
DNA/RNA 
37 exons, spanning about 120 kb; 13-15 mRNA 
Protein 
3969 amino acids, 431 kDa; Transcriptional 
regulatory factor. MLL is known to be associated 
with more than 30 proteins, including the core 
components of the SWI/SNF chromatin remodeling 
complex and the transcription complex TFIID. MLL 
binds promotors of HOX genes through acetylation 
and methylation of histones. MLL is a major 
regulator of hematopoesis and embryonic 
development, through regulation of HOX genes 
expression regulation (HOXA9 in particular). 
AFDN 
Location 
6q27 
Note 
AFDN was previously called MLLT4 
(myeloid/lymphoid or mixed-lineage leukemia; 
translocated to, 4) or AF6 (ALL1 fused gene from 
chromosome 6) 
Protein 
The protein, called afadin, is a scaffolding protein 
with a role in cell-cell junctional complexes 
(adherens junctions and in tight junctions). The 
transmembrane proteins cadherins and nectins 
interact with other proteins through their 
cytoplasmic domain to form adherens junctions. 
CTNNA1, CTNNA2 or CTNNA3 (α-catenins) 
/CTNNB1 (β-catenin) links cadherins to the actin 
cytoskeleton and afadin links nectins to the actin 
cytoskeleton (Boettner et al., 2000; Tachibana et al., 
2000; Bégay-Müller et al., 2002). Afadin plays an 
essential role in regulating apical-basal polarity and 
adherens junction integrity (Rakotomamonjy et al., 
2017).  
 
Loss of expression or lower expression of afadin is 
found in pancreatic cancer, and is correlated with 
poor prognosis in colon cancer and breast cancer, 
induces cell migration and cell invasion of 
myometrium in endometrial cancer, where it is 
associated with high histological grades (Fournier et 
al., 2011; Sun et al., 2014; Xu et al., 2015; 
Yamamoto et al., 2015a). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
The breakpoint in AFDN (AF6, MLLT4) was 
determined from two AML, one T-ALL, and one cell 
line. It was found between exons 1 and 2, 
corresponding to the junction of amino acid 35 and 
36 (Tanabe et al., 1996); i.e.  
 
MSAGGRDEERRKLADIIHHWNANRLDLFEIS
QPTE/DLEFHGVMRFYFQDKAAGNFATKCIRV
SSTATTQD  
 
In 8 of 8 AML adult cases, MLL exon/intron 8 was 
fused to AFDN (AF6, MLLT4) exon/intron 1 
(Lavallee et al 2015).  
 
In the large study of 95 cases of acute leukemia with 
t(6;11); the breakpoint in MLL was more often in 
intron 9 (65% on cases) than it was in other fusions 
(e.g. AFF1 (AF4): 33%, MLLT3 (AF9): 38%, 
MLLT1 (ENL): 23%, where intron 11 is equally or 
more frequent). The breakpoint was in: intron 9: 62 
cases, exon 10: 4 cases, intron 10: 15 cases, exon 11: 
4 cases, intron 11: 3 cases, exon 12: 2 cases. Only in 
MLL/AFDN cases were observed very unusual MLL 
breakpoints (n=4), within intron 21 and 23. The 
authors pointed out that "This is quite important 
t(6;11)(q27;q23) KMT2A/AFDN  
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because such a far away downstream breakpoint 
includes the complete PHD1-3, the BD domain as 
well as the complete ePHD4 domain of MLL into the 
fusion protein with AFDN (AF6, MLLT4). These 
additional 581 amino acids could be an important 
hint for the importance of these MLL domains in T-
ALL. The PHD1-3 and bromodomain exert 
important regulatory functions to the MLL N-
terminus, like chromatin reading, protein stability or 
PPIE (CYP33) binding. In the latter case, binding of 
the BMI1 repressor complex will reverse the 
function of the MLL/AFDN fusion by repressing 
gene transcription" (Meyer et al., 2017). 
Fusion protein 
 
t(6;11)(q27;q23) MLL/AFDN 
 
Oncogenesis 
While AFDN localizes in the cytoplasm, 
MLL/AFDN localizes in the nucleus, leading to 
aberrant activation of RAS and of its downstream 
targets (Deshpande et al., 2013; Manara et al. 2014). 
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